

Pool of Potential 2007 Physician Measures for
Physician Voluntary Reporting Program (PVRP)

As of: October 16, 2006

SUBJECT TO MODIFICATION

Presented in order of medical specialty share of Medicare physician spending, highest to lowest

SPECIALTY (Number of Measures)	CLINICAL TOPIC	MEASURE STATEMENT	AQA VOTE EXPECTED	NQF ENDORSEMENT VOTE EXPECTED
Internal Medicine (21)	Behavioral Health	(1) Antidepressant medication during acute phase for patient with new episode of major depression	Adopted	Endorsed
	Coronary Artery Disease	(2) Beta blocker for prior myocardial infarction	Adopted	Endorsed
	Diabetes: Hemoglobin A1C Control	(3) Hemoglobin A1c control in Type 1 or 2 diabetes mellitus	Adopted	Endorsed
	Diabetes: Lipid Control	(4) Low density lipoprotein control in Type 1 or 2 diabetes mellitus	Adopted	Endorsed
	Diabetes: Blood Pressure Control	(5) High blood pressure control in Type 1 or 2 diabetes mellitus	Adopted	Endorsed
	Geriatrics: Urinary Incontinence	(6) Behavioral therapy assessment	1/22/2007	5/21/2007
	Geriatrics: Urinary Incontinence	(7) Assessment of presence or absence of urinary incontinence in women aged 65 years and older	1/22/2007	5/21/2007
	Geriatrics: Urinary Incontinence	(8) Characterization of urinary incontinence in women aged 65 years and older	1/22/2007	5/21/2007
	Geriatrics: Urinary Incontinence	(9) Plan of care for urinary incontinence in women aged 65 years and older	1/22/2007	5/21/2007
	Geriatrics: Falls	(10) Assessment of elderly for falls	1/22/2007	5/21/2007
	Geriatrics: Falls	(11) Identification of high risk for falls	1/22/2007	5/21/2007
	Geriatrics: Falls	(12) Risk assessment for falls	1/22/2007	5/21/2007
	Geriatrics: Falls	(13) Plan of care for falls	1/22/2007	5/21/2007
	Geriatrics: Falls	(14) Screening for falls	1/22/2007	5/21/2007
	Geriatrics: Care coordination	(15) Medication reconciliation	1/22/2007	5/21/2007
	Geriatrics: Advance Care	(16) Advance care planning	1/22/2007	5/21/2007
	Heart Failure	(17) Angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy for left ventricular systolic dysfunction (LVSD)	Adopted	Endorsed
	Chronic Obstructive Pulmonary Disease (COPD)	(18) Patients with spirometry results documented with either FEV1 (forced expiratory vital) capacity value or FEV1/FVC (forced vital capacity) value	1/22/2007	Endorsed
	Chronic Obstructive Pulmonary Disease (COPD)	(19) Symptomatic patients who were prescribed an inhaled bronchodilator	1/22/2007	Endorsed
	Asthma: Symptoms Evaluation	(20) Percent of patients who were evaluated during at least one office visit during the reporting year for the frequency (numeric) of daytime and nocturnal asthma symptoms	1/22/2007	Endorsed

SPECIALTY (Number of Measures)	CLINICAL TOPIC	MEASURE STATEMENT	AQA VOTE EXPECTED	NOF ENDORSEMENT VOTE EXPECTED
Internal Medicine (con.'t) (21)	Asthma: Pharmacologic Treatment	(21) Percent of patients with mild, moderate, or severe persistent asthma who were prescribed either the preferred long-term control medication (inhaled corticosteroid)* or an acceptable alternative treatment	Adopted	Endorsed
Cardiology (8)	Coronary Artery Disease	(1) Percent of coronary artery disease patients with diabetes and/or left ventricular systolic dysfunction (LVSD) who were prescribed angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy	Adopted	Endorsed
	Coronary Artery Disease	(2) Percent of coronary artery disease patients who were prescribed antiplatelet therapy	Adopted	Endorsed
	Coronary Artery Disease	(3) Percent of coronary artery disease patients who received at least one lipid profile (or ALL component tests)	Adopted	Endorsed
	Coronary Artery Disease	(4) Beta blocker for prior myocardial infarction	Adopted	Endorsed
	Coronary Artery Disease	(5) Percent of heart failure patients quantitative or qualitative results of left ventricular failure assessment recorded	Adopted	Endorsed
	Heart Failure	(6) Percent of heart failure patients prescribed angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy for left ventricular systolic dysfunction (LVSD)	Adopted	Endorsed
	Heart Failure	(7) percent of heart failure patients with left ventricular systolic dysfunction (LVSD) who were prescribed beta-blocker therapy	Adopted	Endorsed
	Heart Failure	(8) Percent of heart failure patients with paroxysmal or chronic atrial fibrillation who were prescribed warfarin therapy	Adopted	Endorsed
Radiology (2)	Acute stroke evaluation	(1) CT(computed tomography) or MRI (magnetic resonance imaging) scan to assess for hemorrhaging, acute infarction, or mass	10/24/2006	4/9/2007
	Acute stroke evaluation	(2) Carotid imaging studies for transient ischemic attack (TIA) and ischemic stroke	10/24/2006	4/9/2007
Ophthalmology (9)	Primary open-angle glaucoma (POAG)	(1) Intraocular pressure (IOP) measurement	10/24/2006	5/21/2007
	Primary open-angle glaucoma (POAG)	(2) Optic nerve evaluation	10/24/2006	5/21/2007
	Age-related macular degeneration (AMD)	(3) Antioxidant supplement prescribed	10/24/2006	5/21/2007
	Age-related macular degeneration (AMD)	(4) Documentation of macular thickening or hemorrhage and level of severity	10/24/2006	5/21/2007
	Cataracts	(5) Assessment of visual functional status	10/24/2006	5/21/2007
	Cataracts	(6) Presurgical documentation of axial length, corneal power measurement and method of intraocular lens power calculation	10/24/2006	5/21/2007
	Cataracts	(7) Presurgical fundus evaluation	10/24/2006	5/21/2007
	Diabetic Retinopathy	(8) Documentation of macular edema and level of severity	10/24/2006	5/21/2007
	Diabetic Retinopathy	(9) Communication with primary care physician	10/24/2006	5/21/2007

SPECIALTY (Number of Measures)	CLINICAL TOPIC	MEASURE STATEMENT	AQA VOTE EXPECTED	NOF ENDORSEMENT VOTE EXPECTED
Family Practice (21)	Behavioral Health	(1) Antidepressant medication during acute phase for patient with new episode of major depression	Adopted	Endorsed
	Coronary Artery Disease	(2) Beta blocker for prior myocardial infarction	Adopted	Endorsed
	Diabetes: Hemoglobin A1C Control	(3) Hemoglobin A1c control in Type 1 or 2 diabetes mellitus	Adopted	Endorsed
	Diabetes: Lipid Control	(4) Low density lipoprotein control in Type 1 or 2 diabetes mellitus	Adopted	Endorsed
	Diabetes: Blood Pressure Control	(5) High blood pressure control in Type 1 or 2 diabetes mellitus	Adopted	Endorsed
	Geriatrics: Urinary Incontinence	(6) Behavioral therapy assessment	1/22/2007	5/21/2007
	Geriatrics: Urinary Incontinence	(7) Assessment of presence or absence of urinary incontinence in women aged 65 years and older	1/22/2007	5/21/2007
	Geriatrics: Urinary Incontinence	(8) Characterization of urinary incontinence in women aged 65 years and older	1/22/2007	5/21/2007
	Geriatrics: Urinary Incontinence	(9) Plan of care for urinary incontinence in women aged 65 years and older	1/22/2007	5/21/2007
	Geriatrics: Falls	(10) Assessment of elderly for falls	1/22/2007	5/21/2007
	Geriatrics: Falls	(11) Identification of high risk for falls	1/22/2007	5/21/2007
	Geriatrics: Falls	(12) Risk assessment for falls	1/22/2007	5/21/2007
	Geriatrics: Falls	(13) Plan of care for falls	1/22/2007	5/21/2007
	Geriatrics: Falls	(14) Screening for falls	1/22/2007	5/21/2007
	Geriatrics: Care coordination	(15) Medication reconciliation	1/22/2007	5/21/2007
	Geriatrics: Advance Care	(16) Advance care planning	1/22/2007	5/21/2007
	Heart Failure	(17) Angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy for left ventricular systolic dysfunction (LVSD)	Adopted	Endorsed
	Chronic Obstructive Pulmonary Disease (COPD)	(18) Patients with spirometry results documented with either FEV1 (forced expiratory vital) capacity value or FEV1/FVC (forced vital capacity) value	1/22/2007	Endorsed
	Chronic Obstructive Pulmonary Disease (COPD)	(19) Symptomatic patients who were prescribed an inhaled bronchodilator	1/22/2007	Endorsed
	Asthma: Symptoms Evaluation	(20) Percent of patients who were evaluated during at least one office visit during the reporting year for the frequency (numeric) of daytime and nocturnal asthma symptoms	1/22/2007	Endorsed
	Asthma: Pharmacologic Treatment	(21) Percent of patients with mild, moderate, or severe persistent asthma who were prescribed either the preferred long-term control medication (inhaled corticosteroid)* or an acceptable alternative treatment	Adopted	Endorsed
Orthopedic Surgery (5)	Infection Prevention	(1) Antibiotic prophylaxis	1/22/2007	5/21/2007

SPECIALTY (Number of Measures)	CLINICAL TOPIC	MEASURE STATEMENT	AQA VOTE EXPECTED	NOF ENDORSEMENT VOTE EXPECTED
Orthopedic Surgery (con.'t) (5)	Deep Vein Thrombosis (DVT) Prevention	(2) Thromboembolism prophylaxis	1/22/2007	5/21/2007
	Care Coordination	(3) Post-fracture – communication with the physician managing on-going care post fracture	1/22/2007	5/21/2007
	Surgical infection prevention	(4) Prophylactic antibiotic selection	1/22/2007	5/21/2007
	Surgical infection prevention	(5) Prophylactic antibiotic discontinuation	1/22/2007	5/21/2007
General Surgery (4)	Infection Prevention	(1) Antibiotic prophylaxis	1/22/2007	5/21/2007
	Deep Vein Thrombosis (DVT) Prevention	(2) Thromboembolism prophylaxis	1/22/2007	5/21/2007
	Surgical infection prevention	(3) Prophylactic antibiotic selection	1/22/2007	5/21/2007
	Surgical infection prevention	(4) Prophylactic antibiotic discontinuation	1/22/2007	5/21/2007
Dermatology (3)	Melanoma	(1) Patient medical history	10/24/2006	5/21/2007
	Melanoma	(2) Complete physical skin examination	10/24/2006	5/21/2007
	Melanoma	(3) Counseling on self-examination	10/24/2006	5/21/2007
Hematology (4)	Myelodysplastic Syndrome	(1) Cytogenetic testing on bone marrow	1/22/2007	Vote Unknown [Send Spring 2007]
	Erythropoietin Theratpy	(2) Iron stores prior to erythropoietin/darbepoeitin therapy	1/22/2007	Vote Unknown [Send Spring 2007]
	Chronic Lymphocytic Leukemia (CLL) Multiple Myeloma	(3) Multiple myeloma treated with biophosphonates	1/22/2007	Vote Unknown [Send Spring 2007]
	Acute Leukemia	(4) Flow cytometry evaluation in chronic lymphocytic leukemia patients	1/22/2007	Vote Unknown [Send Spring 2007]
Urology (4)	Infection Prevention	(1) Antibiotic prophylaxis	1/22/2007	4/9/2007
	Deep Vein Thrombosis (DVT) Prevention	(2) Thromboembolism prophylaxis	1/22/2007	4/9/2007
	Surgical Infection Prevention	(3) Prophylactic antibiotic selection	1/22/2007	4/9/2007
	Surgical Infection Prevention	(4) Prophylactic antibiotic discontinuation	1/22/2007	4/9/2007
Emergency Medicine (8)	Coronary Artery Disease	(1) Aspirin on arrival for acute myocardial infarction	1/22/2007	5/21/2007
	Acute myocardial infarction	(2) Electrocardiogram for chest pain	1/22/2007	5/21/2007
	Syncope	(3) Electrocardiogram for syncope	1/22/2007	5/21/2007
	Pneumonia	(4) Antibiotic administration for pneumonia	1/22/2007	5/21/2007
	Pneumonia	(5) Follow-up care for pneumonia	1/22/2007	5/21/2007
	Pneumonia	(6) Vital signs for pneumonia	1/22/2007	5/21/2007
	Pneumonia	(7) Oxygen saturation assessment for pneumonia	1/22/2007	5/21/2007
	Pneumonia	(8) Empiric antibiotic for pneumonia	1/22/2007	5/21/2007

SPECIALTY (Number of Measures)	CLINICAL TOPIC	MEASURE STATEMENT	AQA VOTE EXPECTED	NOF ENDORSEMENT VOTE EXPECTED
Gastroenterology (8)	Infection Prevention	(1) Antibiotic prophylaxis	1/22/2007	5/21/2007
	Deep Vein Thrombosis (DVT) Prevention	(2) Thromboembolism prophylaxis	1/22/2007	5/21/2007
	Gastro-esophageal Reflux Disease (GERD)	(3) Assessment for alarm symptoms	1/22/2007	5/21/2007
	Gastro-esophageal Reflux Disease (GERD)	(4) Endoscopy for patients with alarm symptoms	1/22/2007	5/21/2007
	Gastro-esophageal Reflux Disease (GERD)	(5) Endoscopy report	1/22/2007	5/21/2007
	Gastro-esophageal Reflux Disease (GERD)	(6) Biopsy for Barrett's esphaagus	1/22/2007	5/21/2007
	Gastro-esophageal Reflux Disease (GERD)	(7) Barium swallow appropriateness - inappropriate use	1/22/2007	5/21/2007
	Gastro-esophageal Reflux Disease (GERD)	(8) Long-term medication therapy – assessment of GERD symptoms	1/22/2007	5/21/2007
Pulmonary Disease (4)	Chronic Obstructive Pulmonary Disease (COPD)	(1) Patients with spirometry results documented with either FEV1 (forced expiratory vital) capacity value or FEV1/FVC (forced vital capacity) value	1/22/2007	Endorsed
	Chronic Obstructive Pulmonary Disease (COPD)	(2) Symptomatic patients who were prescribed an inhaled bronchodilator	1/22/2007	Endorsed
	Asthma: Symptoms Evaluation	(3) Percent of patients who were evaluated during at least one office visit during the reporting year for the frequency (numeric) of daytime and nocturnal asthma symptoms	1/22/2007	Endorsed
	Asthma: Pharmacologic Treatment	(4) Percent of patients with mild, moderate, or severe persistent asthma who were prescribed either the preferred long-term control medication (inhaled corticosteroid)* or an acceptable alternative treatment	Adopted	Endorsed
Anesthesiology (1)	Surgical infection prevention	(1) Prophylactic antibiotic timing	1/22/2007	5/21/2007
Neurology (9)	Stroke and Stroke Rehabilitation	(1) Deep vein thrombosis (DVT) prophylaxis	10/24/2006	4/9/2007
	Stroke and Stroke Rehabilitation	(2) Antiplatelet or anticoagulant at discharge	10/24/2006	4/9/2007
	Stroke and Stroke Rehabilitation	(3) Anticoagulant for patients with atrial fibrillation	10/24/2006	4/9/2007
	Stroke and Stroke Rehabilitation	(4) Tissue plasminogen activator (tPA) considered	10/24/2006	4/9/2007

SPECIALTY (Number of Measures)	CLINICAL TOPIC	MEASURE STATEMENT	AQA VOTE EXPECTED	NOF ENDORSEMENT VOTE EXPECTED
Neurology (con.'t) (9)	Stroke and Stroke Rehabilitation	(5) Antithrombotic given within 48 hours	10/24/2006	4/9/2007
	Stroke and Stroke Rehabilitation	(6) Screen for dysphagia	10/24/2006	4/9/2007
	Stroke and Stroke Rehabilitation	(7) Plan for rehabilitation considered	10/24/2006	4/9/2007
	Stroke and Stroke Rehabilitation	(8) Administration of heparin (overuse)	10/24/2006	4/9/2007
	Stroke and Stroke Rehabilitation	(9) Acute stroke evaluation	10/24/2006	4/9/2007
Psychiatry (1)	Antidepressant medication management	(1) Antidepressant medication during acute phase for patient with new episode of major depression	Adopted	Endorsed
General Practice (21)	Behavioral Health	(1) Antidepressant medication during acute phase for patient with new episode of major depression	Adopted	Endorsed
	Coronary Artery Disease	(2) Beta blocker for prior myocardial infarction	Adopted	Endorsed
	Diabetes: Hemoglobin A1C Control	(3) Hemoglobin A1c control in Type 1 or 2 diabetes mellitus	Adopted	Endorsed
	Diabetes: Lipid Control	(4) Low density lipoprotein control in Type 1 or 2 diabetes mellitus	Adopted	Endorsed
	Diabetes: Blood Pressure Control	(5) High blood pressure control in Type 1 or 2 diabetes mellitus	Adopted	Endorsed
	Geriatrics: Urinary Incontinence	(6) Behavioral therapy assessment	1/22/2007	5/21/2007
	Geriatrics: Urinary Incontinence	(7) Assessment of presence or absence of urinary incontinence in women aged 65 years and older	1/22/2007	5/21/2007
	Geriatrics: Urinary Incontinence	(8) Characterization of urinary incontinence in women aged 65 years and older	1/22/2007	5/21/2007
	Geriatrics: Urinary Incontinence	(9) Plan of care for urinary incontinence in women aged 65 years and older	1/22/2007	5/21/2007
	Geriatrics: Falls	(10) Assessment of elderly for falls	1/22/2007	5/21/2007
	Geriatrics: Falls	(11) Identification of high risk for falls	1/22/2007	5/21/2007
	Geriatrics: Falls	(12) Risk assessment for falls	1/22/2007	5/21/2007
	Geriatrics: Falls	(13) Plan of care for falls	1/22/2007	5/21/2007
	Geriatrics: Falls	(14) Screening for falls	1/22/2007	5/21/2007
	Geriatrics: Care coordination	(15) Medication reconciliation	1/22/2007	5/21/2007
	Geriatrics: Advance Care	(16) Advance care planning	1/22/2007	5/21/2007
	Heart Failure	(17) Angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy for left ventricular systolic dysfunction (LVSD)	Adopted	Endorsed
	Chronic Obstructive Pulmonary Disease (COPD)	(18) Patients with spirometry results documented with either FEV1 (forced expiratory vital) capacity value or FEV1/FVC (forced vital capacity) value	1/22/2007	Endorsed

SPECIALTY (Number of Measures)	CLINICAL TOPIC	MEASURE STATEMENT	AQA VOTE EXPECTED	NOF ENDORSEMENT VOTE EXPECTED
General Practice (con.t) (21)	Chronic Obstructive Pulmonary Disease (COPD)	(19) Symptomatic patients who were prescribed an inhaled bronchodilator	1/22/2007	Endorsed
	Asthma: Symptoms Evaluation	(20) Percent of patients who were evaluated during at least one office visit during the reporting year for the frequency (numeric) of daytime and nocturnal asthma symptoms	1/22/2007	Endorsed
	Asthma: Pharmacologic Treatment	(21) Percent of patients with mild, moderate, or severe persistent asthma who were prescribed either the preferred long-term control medication (inhaled corticosteroid)* or an acceptable alternative treatment	Adopted	Endorsed
Otolaryngology (4)	Surgical Infection Prevention	(1) Prophylactic antibiotic selection	1/22/2007	4/9/2007
	Surgical Infection Prevention	(2) Prophylactic antibiotic discontinuation	1/22/2007	4/9/2007
	Infection Prevention	(3) Antibiotic prophylaxis	1/22/2007	4/9/2007
	Deep Vein Thrombosis (DVT) Prevention	(4) Thromboembolism prophylaxis	1/22/2007	4/9/2007
Nephrology (2)	Dialysis Treatment Adequacy	(1) Dialysis dose in end stage renal disease (ESRD)	1/22/2007	4/9/2007
	Anemia Management	(2) Hematocrit level in end stage renal disease (ESRD)	1/22/2007	4/9/2007
Rheumatology (3)	Treatment/screening Dual x-ray absorptiometry (DXA) [bone density] measurement	(1) General population – screening or therapy for women aged 65 years and older	10/24/2006	5/21/2007
	Pharmacologic treatment	(2) Osteoporosis – pharmacologic therapy	10/24/2006	5/21/2007
	Pharmacologic treatment	(3) Osteoporosis – counseling for vitamin D and calcium intake	10/24/2006	5/21/2007
Neurosurgery (4)	Surgical Infection Prevention	(1) Prophylactic antibiotic selection	1/22/2007	4/9/2007
	Surgical Infection Prevention	(2) Prophylactic antibiotic discontinuation	1/22/2007	4/9/2007
	Infection Prevention	(3) Antibiotic prophylaxis	1/22/2007	4/9/2007
	Deep Vein Thrombosis (DVT) Prevention	(4) Thromboembolism prophylaxis	1/22/2007	4/9/2007
Vascular Surgery (5)	Vascular Access	(1) Arteriovenous fistula (AVF) in end stage renal disease (ESRD)	1/22/2007	4/9/2007
	Surgical Infection Prevention	(2) Prophylactic antibiotic selection	1/22/2007	4/9/2007
	Surgical Infection Prevention	(3) Prophylactic antibiotic discontinuation	1/22/2007	4/9/2007
	Infection Prevention	(4) Antibiotic prophylaxis	1/22/2007	4/9/2007
	Deep Vein Thrombosis (DVT) Prevention	(5) Thromboembolism prophylaxis	1/22/2007	4/9/2007
Thoracic Surgery (6)	Surgical Infection Prevention	(1) Prophylactic antibiotic selection	1/22/2007	4/9/2007
	Surgical Infection Prevention	(2) Prophylactic antibiotic discontinuation	1/22/2007	4/9/2007
	Infection Prevention	(3) Antibiotic prophylaxis	Adopted	4/9/2007
	Deep Vein Thrombosis (DVT) Prevention	(4) Thromboembolism prophylaxis	Adopted	4/9/2007
	Internal Mammary Artery (IMA) Use	(5) IMA in coronary artery bypass graft (CABG)	Adopted	4/9/2007

SPECIALTY (Number of Measures)	CLINICAL TOPIC	MEASURE STATEMENT	AQA VOTE EXPECTED	NOF ENDORSEMENT VOTE EXPECTED
Thoracic Surgery (con.'t) (6)	Pre-Operative Beta Blocker Administration	(6) Pre-operative beta blocker in coronary artery bypass graft (CABG)	Adopted	4/9/2007
Obstetrics/ Gynecology (4)	Infection Prevention	(1) Antibiotic prophylaxis	1/22/2007	4/9/2007
	Deep Vein Thrombosis (DVT) Prevention	(2) Thromboembolism prophylaxis	1/22/2007	4/9/2007
	Pharmacologic treatment	(3) Osteoporosis – pharmacologic therapy	1/22/2007	5/21/2007
	Pharmacologic treatment	(4) Osteoporosis – counseling for vitamin D and calcium intake	1/22/2007	5/21/2007
Cardiac Surgery (6)	Surgical Infection Prevention	(1) Prophylactic antibiotic selection	1/22/2007	4/9/2007
	Surgical Infection Prevention	(2) Prophylactic antibiotic discontinuation	1/22/2007	4/9/2007
	Infection Prevention	(3) Antibiotic prophylaxis	Adopted	4/9/2007
	Deep Vein Thrombosis (DVT) Prevention	(4) Thromboembolism prophylaxis	Adopted	4/9/2007
	Internal Mammary Artery (IMA) Use	(5) IMA in coronary artery bypass graft (CABG)	Adopted	4/9/2007
	Pre-Operative Beta Blocker Administration	(6) Pre-operative beta blocker in coronary artery bypass graft (CABG)	Adopted	4/9/2007
Plastic Surgery (4)	Surgical Infection Prevention	(1) Prophylactic antibiotic selection	1/22/2007	4/9/2007
	Surgical Infection Prevention	(2) Prophylactic antibiotic discontinuation	1/22/2007	4/9/2007
	Infection Prevention	(3) Antibiotic prophylaxis	1/22/2007	4/9/2007
	Deep Vein Thrombosis (DVT) Prevention	(4) Thromboembolism prophylaxis	1/22/2007	4/9/2007
Endocrinology (4)	Diabetes: Hemoglobin A1C Control	(1) Hemoglobin A1c control in Type 1 or 2 diabetes mellitus	Adopted	Endorsed
	Diabetes: Lipid Control	(2) Low density lipoprotein control in Type 1 or 2 diabetes mellitus	Adopted	Endorsed
	Diabetes: Blood Pressure Control	(3) High blood pressure control in Type 1 or 2 diabetes mellitus	Adopted	Endorsed
	Treatment/screening Dual x-ray absorptiometry (DXA) [bone density] measurement	(4) General population – screening or therapy for women aged 65 years and older	1/22/2007	5/21/2007
Allergy & Immunology (2)	Asthma: Symptoms Evaluation	(1) Percent of patients who were evaluated during at least one office visit during the reporting year for the frequency (numeric) of daytime and nocturnal asthma symptoms	1/22/2007	Endorsed
	Asthma: Pharmacologic Treatment	(2) Percent of patients with mild, moderate, or severe persistent asthma who were prescribed either the preferred long-term control medication (inhaled corticosteroid)* or an acceptable alternative treatment	Adopted	Endorsed
Critical Care (2)	Myocardial Infarction	(1) Aspirin at arrival for acute myocardial infarction (AMI)	Adopted	Endorsed
	Myocardial Infarction	(2) Beta blocker at arrival for acute myocardial infarction (AMI)	Adopted	Endorsed

SPECIALTY (Number of Measures)	CLINICAL TOPIC	MEASURE STATEMENT	AQA VOTE EXPECTED	NOF ENDORSEMENT VOTE EXPECTED
Geriatrics (11)	Geriatrics: Urinary Incontinence	(1) Behavioral therapy assessment	1/22/2007	5/21/2007
	Geriatrics: Urinary Incontinence	(2) Assessment of presence or absence of urinary incontinence in women Aged 65 years and older	1/22/2007	5/21/2007
	Geriatrics: Urinary Incontinence	(3) Characterization of urinary incontinence in women aged 65 years and older	1/22/2007	5/21/2007
	Geriatrics: Urinary Incontinence	(4) Plan of care for urinary incontinence in aomen aged 65 years and older	1/22/2007	5/21/2007
	Geriatrics: Falls	(5) Assessment of elderly for falls	1/22/2007	5/21/2007
	Geriatrics: Falls	(6) Identification of high risk for falls	1/22/2007	5/21/2007
	Geriatrics: Falls	(7) Risk assessment for falls	1/22/2007	5/21/2007
	Geriatrics: Falls	(8) Plan of care for falls	1/22/2007	5/21/2007
	Geriatrics: Falls	(9) Screening for falls	1/22/2007	5/21/2007
	Geriatrics: Care coordination	(10) Medication reconciliation	1/22/2007	5/21/2007
	Geriatrics: Advance Care	(11) Advance care planning	1/22/2007	5/21/2007
Colo-Rectal Surgery (4)	Surgical Infection Prevention	(1) Prophylactic antibiotic selection	1/22/2007	4/9/2007
	Surgical Infection Prevention	(2) Prophylactic antibiotic discontinuation	1/22/2007	4/9/2007
	Infection Prevention	(3) Antibiotic prophylaxis	1/22/2007	4/9/2007
	Deep Vein Thrombosis (DVT) Prevention	(4) Thromboembolism prophylaxis	1/22/2007	4/9/2007
Pediatrics (4)	Asthma: Symptoms Evaluation	(1) Percent of patients who were evaluated during at least one office visit during the reporting year for the frequency (numeric) of daytime and nocturnal asthma symptoms	1/22/2007	Endorsed
	Asthma: Pharmacologic Treatment	(2) Percent of patients with mild, moderate, or severe persistent asthma who were prescribed either the preferred long-term control medication (inhaled corticosteroid)* or an acceptable alternative treatment	Adopted	Endorsed
	Overuse or Misuse	(3) Percent of patients who were given a diagnosis of upper respiratory infection and were not dispensed an antibiotic prescription on or 3 days after the episode date	Adopted	Endorsed
	Overuse or Misuse	(4) Percent of patients who were diagnosed with pharyngitis, prescribed an antibiotic and who received a group A streptococcus test for the episode	Adopted	Endorsed
Hand Surgery (4)	Surgical Infection Prevention	(1) Prophylactic antibiotic selection	1/22/2007	4/9/2007
	Surgical Infection Prevention	(2) Prophylactic antibiotic discontinuation	1/22/2007	4/9/2007
	Infection Prevention	(3) Antibiotic prophylaxis	1/22/2007	4/9/2007
	Deep Vein Thrombosis (DVT) Prevention	(4) Thromboembolism prophylaxis	1/22/2007	4/9/2007